Market Overview

UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk

Related KERX
6 U.S.-Listed Stocks Short Sellers Are Strongly Betting Against
Keryx Pharma: Brean Says Today Undermines Bear Points On Co., Lowers PT To $18 From $22, Maintains Buy

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), but lowered the price target from $27.00 to $21.00.

In the report, MLV & Co noted, “KERX reported 1Q results last week, but the main focus was mgmt's comments on the call surrounding outstanding CMC issues with the NDA for lead asset Zerenex (hyperphosphatemia). We hadn't previously been aware of CMC issues, and while KERX has provided add'l data on this (as well as drug-drug interactions, with info on both recently requested by FDA), we were disappointed to hear of this latest update. With the Zerenex PDUFA just one month away (June 7) and mgmt on multiple occasions citing ‘there are no guarantees' (yes, we applaud the transparency), we're feeling a bit less confident in an on-time approval.

"We don't model a delay for Zerenex at this time, but given the increased risk in a potential on-time FDA approval, we now increase the discount rate in our DCF from 17.5% to 20%, and as a result, lower our 1-yr PT to $21 (vs. prior $27, but still 73% upside).”

Keryx Biopharmaceuticals closed on Friday at $12.11.

Latest Ratings for KERX

Aug 2015Morgan StanleyInitiates Coverage onUnderweight
Aug 2015Roth CapitalDowngradesBuyNeutral
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

Posted-In: Graig C. Suvannavejh MLV & CoAnalyst Color Price Target Analyst Ratings


Related Articles (KERX)

Get Benzinga's Newsletters